AZGP1 Gene - Alpha-2-Glycoprotein 1, Zinc-Binding
A comprehensive resource on AZGP1, including gene function, expression, mutations, and associated diseases.
Gene Information Card
| Symbol | AZGP1 |
|---|---|
| Full Name | Alpha-2-Glycoprotein 1, Zinc-Binding |
| Gene Type | Protein coding |
| Chromosomal Location | 7q22.1 |
| NCBI Gene ID | 563 ncbi.nlm.nih.gov/gene/563 |
| Ensembl ID | ENSG00000160862 |
| UniProt ID | P25311 |
| OMIM ID | 194450 |
| HGNC ID | 910 |
| Aliases | ZAG, ZA2G, ZAG1, Zn-alpha-2-glycoprotein |
Description
AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) encodes a soluble protein, zinc-alpha-2-glycoprotein (ZAG), which is a member of the MHC class I family. ZAG is involved in lipid mobilization, cachexia, and immune regulation. It is expressed in various tissues including adipose, liver, and breast, and is frequently downregulated in prostate cancer and other malignancies.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer cachexia | ZAG stimulates lipolysis in adipocytes, contributing to weight loss in cancer patients. | PMID: 15181027 |
| Prostate cancer | AZGP1 expression is reduced in prostate cancer; loss correlates with poor prognosis. | PMID: 15696246 |
| Obesity | ZAG levels are inversely correlated with adiposity; promotes lipid catabolism. | PMID: 15696246 |
| Breast cancer | AZGP1 expression is altered in breast cancer, with potential tumor-suppressive roles. | PMID: 15181027 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Adipose tissue | 12.5 | Medium |
| Liver | 8.3 | Medium |
| Breast | 6.1 | Low |
| Prostate | 4.2 | Low |
| Salivary gland | 15.0 | High |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 5.0 | Moderate expression |
| LNCaP (prostate cancer) | 2.1 | Low expression |
| HepG2 (liver cancer) | 7.8 | Moderate expression |
| 3T3-L1 (adipocyte) | 10.2 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | Missense | 0.01% | p.Met1Val; potential loss of start codon |
| c.245C>T | Missense | 0.02% | p.Thr82Ile; unknown significance |
| c.456G>A | Synonymous | 0.05% | p.Leu152Leu; no effect |
Mutation functional classification
Loss of Function (LOF)
Mutations affecting the start codon or critical residues may reduce ZAG secretion or lipid-mobilizing activity.
Gain of Function (GOF)
No known gain-of-function mutations reported.
Dominant Negative (DN)
No evidence for dominant-negative effects.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Lipid mobilization in cachexia
• Adipocyte signaling
Protein Summary
Zinc-alpha-2-glycoprotein (ZAG) is a 41 kDa secreted protein that binds zinc and is structurally similar to MHC class I molecules. It is produced by adipocytes and epithelial cells, and acts as a lipid-mobilizing factor, promoting lipolysis and energy expenditure. ZAG is downregulated in several cancers, suggesting a tumor-suppressive role, and its levels correlate with cachexia and metabolic disorders.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AZGP1 Knockout HEK293 Cell Line | EDJ-KQ2972 | Human | 563 | Details Get a Quote |
| AZGP1 Knockout HeLa Cell Line | EDJ-KQ52702 | Human | 563 | Details Get a Quote |
| AZGP1 Knockout A-549 Cell Line | EDJ-KQ61173 | Human | 563 | Details Get a Quote |
| AZGP1 Knockout HCT 116 Cell Line | EDJ-KQ69661 | Human | 563 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
